Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes Among Patients With BRAF-Positive Metastatic Melanoma

Clinical trial NCT06251934 · COMPLETED

Trial details

NCT number: NCT06251934
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Study type: OBSERVATIONAL

BRAF-positive Metastatic Melanoma

Start date: 2022-09-28
Primary completion: 2022-11-01
Enrollment: 785

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.